Cerity Partners
PTGX icon

Cerity Partners’s Protagonist Therapeutics PTGX Stock Holding History

Cerity Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$804K Buy
6,563
+870
+15% +$90.9K ﹤0.01% 2123
2026
Q1 		$600K Sell
5,693
-3,356
-37% -$297K ﹤0.01% 2168
2025
Q4 		$790K Buy
9,049
+431
+5% +$35.3K ﹤0.01% 1827
2025
Q3 		$572K Sell
8,618
-1,104
-11% -$62.8K ﹤0.01% 1891
2025
Q2 		$537K Buy
9,722
+477
+5% +$22.9K ﹤0.01% 1817
2025
Q1 		$447K Sell
9,245
-3,811
-29% -$160K ﹤0.01% 1829
2024
Q4 		$518K Sell
13,056
-1,185
-8% -$51.7K ﹤0.01% 1736
2024
Q3 		$641K Buy
14,241
+3,005
+27% +$121K ﹤0.01% 1636
2024
Q2 		$389K Sell
11,236
-690
-6% -$20.2K ﹤0.01% 1672
2024
Q1 		$345K Buy
11,926
+661
+6% +$18K ﹤0.01% 1788
2023
Q4 		$258K Hold
11,265
– – ﹤0.01% 1600
2023
Q3 		$188K Sell
11,265
-725
-6% -$14.1K ﹤0.01% 1287
2023
Q2 		$331K Hold
11,990
– – ﹤0.01% 1354
2023
Q1 		$276K Buy
+11,990
New +$201K ﹤0.01% 1563
2022
Q3 		– Sell
-11,640
Closed -$92K – 1242
2022
Q2 		$92K Buy
+11,640
New +$141K ﹤0.01% 1134

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cerity Partners's PTGX Position: Q2 2026 in Review

Cerity Partners increased its Protagonist Therapeutics (PTGX) stake by 15% in Q2 2026, buying an estimated $90.9K and bringing the position to 6,563 shares worth $804K. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Cerity Partners first reported a position in PTGX in Q2 2022 and has held it in 15 quarters since. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Cerity Partners held 6,563 shares of Protagonist Therapeutics worth $804K as of Q2 2026.
  • Cerity Partners bought 870 Protagonist Therapeutics shares in Q2 2026, an estimated $90.9K.
  • Protagonist Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2123 holding.
  • Cerity Partners first reported a position in Protagonist Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.